“The gene therapy is a method used to treat genetic disorders by introducing a wild type gene in place the faulty gene into the affected cell using a vector.”
The gene therapy is one of the challenging ongoing research in genetics, yet it is most promising.
We can prevent any genetic defect using it, also, the inherited genetic defects such as thalassemia and sickle cell anaemia can also be prevented.
So many other disorders are adding every day in the list of gene therapy and that is why a successful gene targeting technology, a gene therapy, is a must needed technology in forthcoming years for mankind.
The normal functional protein can be revived by replacing a mutant gene with a wild type one. However, it is not as easy as we are discussing, it has many challenges to face.
In this present article, we will talk on those challenges and how to overcome them with some other ongoing research on gene therapy.
Also, various approaches to gene therapy are described in the present article.
Experiment on the model organism demonstrated that the use of successful gene therapy for hereditary disorders are still a long way off. However, promising results are gained for cancer and some monogenic disorders.
The first successful gene transfer on a patient was done in the year 1989.
In the present article, our major focus will be on different types of vectors used in gene therapy in addition to some of the examples of it.
- History of Gene therapy
- What is gene therapy?
- Type of gene therapy
- The different technique of gene therapy
- Vectors for gene therapy
- Viral vectors
- Non-viral vector
- Stepwise process of gene therapy
- Application of gene therapy
- Limitations of gene therapy
- Challenges and Future aspects
Commonly used abbreviations:
|GOI||Gene of Interest|
|NIH||National Institute of Health|
|FDA||Food and Drug Administration|
|DMD||Duchenne Muscular Dystrophy|
|ITR||Inverted Terminal Repeats|
|HIV||Human Immuno Virus|
|SB||Sleeping Beauty Transposon System|
|siRNA||Smaller Interfering RNA|
|HSV||Herpes Simplex Virus|
Note: The present article mainly focused on the technical aspects of gene therapy, if you want some basic idea and simple explanation, please first read our previous article:
A beginner’s guide to gene therapy: What is Gene Therapy? and How Does it Work?
Now let’s get into the topic,
The concept of gene therapy was originated in the 60s by Rogers and Pfuderer.
In 1961, K Lorraine introduced a functional gene into the cells of mammals.
After several years of it, in 1971, Carl R. Merril experimented on Human Fibroblast cells and concluded that DNA could be inserted into the human genome for fixing the mutant gene.
Later on, in 1972 Theodore Friedman and coworkers successfully corrected the Lesch-Nyhan single gene disorder using gene therapy trials at the National Institute of Health.
Although, Martine Cline was called the pioneer in gene therapy who gave the idea for transferring the gene into a human cell. He had also attempted DNA modification techniques in the year, 1980.
In the year 1984, the first retroviral vector system was introduced by Richard Mulligan for delivering the foreign gene.
In 1990, clinical trial of worlds first approved gene therapy is took place under the close monitoring of NIH.
In the early ’90s, gene therapy chitchat becomes stronger as it entered in the cancer treatment.
In 1992, Trojan and co-workers introduced a concept of using gene therapy in cancer treatment. They had postulated that the introduction of the transgene could trigger off the oncogenic activity.
In 2002, the scientist had successfully treated adenosine deaminase deficiency through gene therapy.
In the same year, sickle cell anaemia mice were treated by introducing the artificial therapeutics gene.
The era for using non-viral vector in gene therapy was begun when polyethylene glycol was first time used as a vector for delivery gene into brain cells in 2003.
The summarised history of the gene therapy is given below,
2006: Two patients were treated for X linked myeloid cell defect using gene therapy.
2006: Lentivirus is used for the treatment of HIV.
2007: Gene therapy trial has begun for inherited retinal disease.
2010: beta thalassemia major child was successfully treated with gene therapy.
2012: FDA approved gene therapy for the beta-thalassemia major treatment.
2014: Adeno-associated virus-mediated gene therapy is used for the treatment of choroideremia disease, a rare form of the x-linked recessive disorder of vision loss. Vision improvement in the patient was noticed after one year.
2014: Clinical trials for the treatment of the sickle cell anaemia was started.
2015: The gene therapy against beta thalassemia (LentiGlobin305) is approved by the FDA. The therapy is mediated by the lentivirus.
2016: Adenosine deaminase deficiency was treated using the “strimvelis” gene therapy product which is later approved for the clinical trial by Europian medical agency.
2017: Another successful clinical trials for the sickle cell gene therapy was done by the French scientists.
2017: FDA approved another gene therapy for ALL (acute lymphoblastic leukaemia) named “tisagenlecleucel.”The treatment was developed by Carl H. June.
2017: FDA approved another gene therapy named “Luxturna” for the treatment of Leber’s congenital amaurosis. It is the first in vivo therapy approved by FDA mediated by the AAV2.
2018: Worlds first ever clinical trial of CRISPR-CAS9 was launched.
2019: The first gene editing therapy in human using ZFN was announced by the Sangamo Therapeutics scientist.
2019: Another gene therapy for the treatment of Spinal muscular atrophy was approved by the FDA.
Commonly used terminologies:
|Transgene||The exogenous gene introduced in the target cell.|
|Vector||Vehicle or an agent to insert transgene in the defective cell.|
|Virion||Mature viral particles|
|Provirus||Reverse transcribed DNA of the retrovirus|
|In vivo||The process performed directly on the living cell or organism.|
|Ex vivo||The process performed on the tissue of the cell outside the body.|
|Tropism||A biological phenomenon for the growth of an organism.|
What is gene therapy?
Introducing a new gene by replacing the mutant gene, is the prime goal of any gene therapy. In the present section, we will understand the mechanism of gene therapy and its types:
Types of gene therapy:
Four types of gene therapy are most popular:
- Somatic cell gene therapy
- Germline gene therapy
- In vivo gene therapy
- Ex vivo gene therapy
The somatic and germline gene therapy are categorized based on the cell type involved in it while the In vivo and ex vivo gene therapy is categorized based on the method of application.
Somatic cell gene therapy:
The cells other than the germline cells are somatic cells. The somatic cells divided by mitosis and engaged in the creation of bone, blood, skin, internal organs and other vital organs and tissues.
46 numbers of chromosome viz 23 pairs are present in somatic cells.
“A mutant gene present only in the somatic cells is replaced using the transgene. Such a method is called somatic cell gene therapy.
The change what we made through the gene therapy remains lifetime only, it will not inherent to the next generation.
The somatic cells are not involved in the reproduction, hence it can not be inherited. Though some ethical issues are involved in the somatic cell gene therapy, the success rate is noticeable.
Gene for the SCGT can be transferred by two ways, virus-mediated gene transfer and liposome-mediated gene transfer.
Although it can be applicable for all the somatic cell types, the common target is the bone marrow.
The cells present in the bone marrow are the only cells that can be divided throughout life and produced different types of blood cells.
Due to this reason, gene therapy is commonly used for blood born disorders such as thalassemia, sickle cell anaemia and haemophilia.
The bone marrow cells are isolated and infected with the virus carrying GOI, the commonly used virus is AAV.
Cells having a transgene are grown into the lab once the gene is inserted at the target location.
New transgenic cells injected back into the bone marrow.
The mechanism of somatic cell gene therapy is shown in the figure below,
Somatic cell gene therapy has several limitations:
- a virus can combine with the host genome and infect the cell (Viral escape).
- Also, if a gene does not insert at the specific location, it may disrupt the function of the normal gene too.
- The chance of activation of oncogene and proto-oncogene is very high.
Germline gene therapy:
“Before splitting the embryo, the GOI is introduced in germ cells (sperm or egg cell), fertilised egg cell or embryo, this method of transferring gene is called germline gene therapy.”
Consequently, the change made in the DNA of these cells can pass it to another generation. Therefore, scientists have divided opinions for germline gene therapy whether it is ethical or not.
Germline gene therapy is prohibited worldwide.
Some of the cells from the reproductive tissues or from the un-split embryo are taken and infected with the viral vector.
The modified cells are grown in the sterile lab environment, care must be taken while doing this. The modified cell must not be infected with other unmodified viruses.
The modified germ cells are used for in vitro fertilization and other artificial reproductive techniques. However, direct injection of a transgene into the embryo is prefered more.
The mechanism of germline gene therapy is shown in the figure below,
In vivo gene therapy:
In the in vivo gene therapy, the exogenous gene is directly inserted into the target cell.
The gene of interest introduced into the body through the aerosols or through injection.
The effect of in vivo gene therapy is restricted to several areas. It introduced GOI only to the affected area, not all the tissues of the body.
The ideal examples of in vivo gene therapy are cystic fibrosis and Duchenne muscular dystrophy.
In the cystic fibrosis, the exogenous gene (or transgene) is introduced through nasal spray (aerosol) whereas in DMD the GOI, a dystrophin gene inserted into the muscle cell through the injection.
Nonetheless, some surrounding cells are infected without any reason and cause some adverse effect.
Conclusively, the in vivo gene therapy is not a good option for inherited disease for now.
Ex vivo gene therapy:
In the ex vivo gene therapy, the cells of mutant tissue are collected, modified outside the body, cultured and transplanted back into the body.
Here none of the process /steps of gene therapy is performed inside the body hence it is called ex vivo.
The ex vivo gene therapy is more controlled and safer because it gives complete control to the researcher.
Although the technique is relevant for those cells which have the potency to divide. Hence only several types of tissues or cells can be altered using ex vivo.
Bone marrow or blood cells are such type of cells often used for the ex vivo gene therapy because the bone marrow cells can divide throughout life.
Why cell must be actively dividing?
The reason behind using only actively dividing cells is that the mutant gene carry cells must have to be removed with the healthy one.
Therefore blood cells and bone marrow cells are the only choices for it.
Because of this reason the ex vivo gene therapy is restricted to some of the blood-related disorders.
Thalassemia, sickle cell anaemia, thrombosis and haemophilia can be treated using this technique.
The steps of the ex vivo gene therapy are listed below,
The defective or mutant cells are isolated from the patient.
The cells are grown into sterile conditions.
Exogenous gene is inserted in the defective cell lines using viral vectors.
The transformed cells are selected and grow in such conditions where it is not infected with other viruses.
The modified cells are now injected back to the patient’s body.
The frequently used vectors for ex vivo gene therapy are retrovirus and AAV.
Using retrovirus, the ψ sequences of it are first removed, so that the virus can not insert their own DNA into the host genome (We had discussed the whole mechanism in the later section of this article).
AAV is an efficient vehicle for ex vivo gene transfer because it can efficiently infect the dividing cells.
Because the ex vivo gene therapy is apt only to dividing cells disorders such as cystic fibrosis or DMD cannot be treated with it.
The success rate of the ex vivo gene therapy depends on the incorporation and expression of a transgene.
We will discuss the haemophilia gene therapy in another article of this series.
Different technique of gene therapy
Any of the genetic diseases caused due to two major reason, the loss of the function mutation or overexpression of a gene.
Based on the technique used, three other types of gene therapy are:
- Gene augmentation therapy
- Gene inhibition therapy
- Suicidal gene therapy
Gene augmentation therapy:
The natural function of a gene is lost due to some of the polymorphism called a loss of function mutation.
Due to the loss of function mutation a normal function protein does not translate.
In the gene augmentation therapy, the mutant (LOF gene) is replaced by the fully functional wild type gene that translates a wild type protein again in the body.
The present technique is majorly used for monogenic disorders.
Cystic fibrosis-like disorders can be treated using gene augmentation therapy.
Gene inhibition therapy:
Overexpression of a gene causes some life-threatening disease conditions like cancer.
Change in the methylation pattern or epigenetic profile of a particular gene results in the overexpression/underexpression of that particular gene.
In the gene inhibition therapy, the overexpressed gene is inhibited by using,
- another gene or DNA sequence
- or by interfering with the activity of the product of that gene.
The present gene therapy is the best choice for an inherited disease, infectious disease and cancer.
The overexpression of the oncogene can be lessened by using this method.
Suicidal gene therapy:
In some types of disease, it is very necessary to kill the cell, especially in cancer.
For those type of cells, some of the genes called suicidal genes are introduced to kill the cells.
The Gene produces a toxic product that induces a strong immune response against that cell leads to cell death.
Suicidal gene therapy is specially designed for cancer therapy.
(Request: purchasing any books from the link given here can help us to grow more).
The vehicles used to introduce the transgene is known as vectors, the utility of the vector depends on the factor enlisted below,
- The size of the exogenous gene (transgene)
- The efficiency of the delivery
- It will induce the host immune response or not
- The stability and longevity of the transgene
- Level of expression of a transgene
“If the selected vector can carry larger transgene that can not induce immune response with good efficiency to infect the cell and higher expression rate, are selected for the gene therapy experiment.”
The classification the gene therapy vectors are given into the figure below,
The vectors are divided into two broader categories:
- Viral vectors
- Non-viral vectors
Some of the common types of virus used in the gene therapy are listed here,
- Adeno associated virus
Now, let’s discuss each vector in detail,
The retrovirus is an RNA virus, the genome of it is made up of the RNA (not DNA). It has two RNA molecule in their genome. Therefore it is also also known as retrovirus-mediated gene therapy.
By the mechanism of reverse transcription, the RNA forms DNA (more specifically called cDNA) and the DNA is integrated into the genome of an organism.
Structurally, the retrovirus contains gag, pol, env genes, long terminal repeats (LTRs) on both the side and Ψ sequences.
The Pol gene encodes for the reverse transcriptase enzyme.
The gag gene encodes for the viral core protein
The env gene encodes for the envelope protein present on the surface of the virus helps in recognition of receptor present on the target cell.
The Ψ sequence required for the packaging of viral particles, therefore these sequences are very important for the virus to infect the host cell, although these sequences are non-coding.
The LTR sequences present on both the ends helps the reverse transcribed DNA to integrate into the host genome.
Read more on retrotransposon:
The structure of retrovirus is given into the figure below,
The retrovirus is one of the best choices for gene therapy, as it can integrate DNA efficiently into the host genome.
The unpacked naked retrovirus is used to fulfil the purpose. If the packaging assembly viz the Ψ sequences are present, it actively involves in the viral-packaging and the virus creates a new viral particle inside the host cell.
Therefore this must be removed first.
Secondly, the virus can activate the oncogenes present into the genome if it is integrated upstream to it.
So once the cell is infected, the altered cell lines must not be contaminated with the replication-competent virus.
Note: The replication-competent virus has the ability to replicate in the host cell.
For the gene therapy experiments three different types of plasmid are used.
- One having the 5′ LTR and an env gene, without the Ψ sequences (plasmid 1).
- Second with the 5′ LTR, gag and pol gene, without the Ψ sequences (plasmid 2).
- Third with both 3′ and 5′ LTR, promoter sequence, a gene of interest and the Ψ sequence sandwiched between both the LTR region (plasmid 3).
See the figure below,
Here the first and second plasmid does not have the Ψ sequence, therefore, it can not produce virion. However, essential pol and gal gene it provides.
The last plasmid contains a gene of interest with the promoter and the Ψ sequence so that the mature virion particles are formed but with the GOI (not gag, pol and env).
After inserting into the host cell, the pol gene encodes for the reverse transcriptase and ensured the integration of target DNA into the host genome.
Interestingly, you will notice one thing that here in both non-virion plasmids only 3′ LTR is present whereas in the third type of plasmid both LTR are present.
The LTR sequence is necessary for insertion of DNA into the host genome. Additionally, the promoter for the retrovirus is located on the 5′ LTR region necessary for the retroviral gene transcription.
Therefore for inhibiting such a viral activity, only 3′ LTR sequences are used in both types of plasmids.
Here the chance of contamination is very high hence each cell lines (altered one) are cross-checked for the presence of replication-competent virus before injected into the patient.
This method is the most advanced and safer.
In another method, along with the retrovirus, the helper virus is used.
The env gene removed from the retrovirus and used to infect the target cell.
The helper virus is also inserted along with it, use as a vector to insert the gene of interest. In this method, the chance of infection is very high as the cell line can be contaminated with both retroviruses as well as a helper virus.
Though the retrovirus-mediated gene therapy is more promising, it has several shortcomings.
It can only infect the dividing cells because it inserts DNA direct on the chromosome. And therefore it is not a good option for DMD and CF, we had already discussed it in the ex vivo gene therapy.
It can only insert DNA up to ~8kb, therefore the size of DNA transfer is limited.
The retrovirus infects all type of body cells, consequently, it is not accurately target-specific. Sometimes the GOI does not reach to the target cell, sometimes it landed in some other type of cells.
Besides, the integration is random, it integrates DNA at any random site in the genome. hence, if it is inserted near the cellular oncogene, it might activate it and can cause cancer.
Also, the retrovirus itself can infect the host cell if it is contaminated.
Murine leukaemia virus is one of the best retrovirus used in gene therapy.
Read the realated articles:
The adenovirus is one of the best choices since long for gene therapy.
The genome of it made up of double-stranded DNA. The size of the genome is 35kb, which is surrounded by the icosahedral capsid made up of 12 different proteins.
It is beneficial over the retrovirus because it can naturally infect the non-dividing cells, especially, cells of respiratory and gastrointestinal tracks.
Because of this reason, it is one of the best opportunities for cystic fibrosis gene therapy.
One other benefit the adenovirus provides among all other vectors is that it can evade the host immune response.
It is also highly-target specific and has controlled integration.
Which means it can only infect or integrate the DNA into their host cells, not other surrounding cells.
Among 50 different serotypes, serotype 3 and 5 have a higher degree of tropism for the respiratory tract cells.
However, due to its harmful effects, it is very necessary to disable the viral replicating mechanism.
The viral gene expression can be divided into early and late phase, for understanding this we have to understand the structure of it.
The virus has the 100bp terminal inverted repeats between which the 35 kb DNA is present.
The expression of the adenovirus divided into two phases the early infection phase and the late phase. The early gene expression is too low and derived from the E1, E2, E3 and E4 region of the genome.
The rest of the region involved in the late expression of the virus.
Clinical trial on the adenovirus revealed that even in the inactive stage adenovirus prompt a strong immune response.
3. Adeno-associated virus:
The genome of the adeno-associated virus is made up of the single-stranded DNA contains only two genes “rep” and “cap”.
Also, the terminal repeats are present on both the ends of it.
The rep gene encodes for the protein that helps the AAV to integrate into the host genome, especially on chromosome 9.
The cap gene encodes for the protein that constructs the capsid of it.
Interestingly, the AAV virus is naturally non-replicative, it required one helper virus to do so. The adenovirus is used to do this function along with the AAV.
Since the AAV can infect both dividing and non-dividing cells, it is the best alternative of the adenovirus.
Majorly, it infects the cells of upper respiratory airways with a long-lasting expression of more than 6 months.
For gene therapy, the rap and cap gene of the AAV is replaced by the transgene. By removing the rep gene, the virus loses its specific integration power on chromosome 9.
The genomic structure of AAV is shown in the figure below,
Due to the long lasting expression of AAV, it is now allowed in human trials for the haemophilia A gene therapy.
The lentivirus is another form of the retrovirus that can even infect the non-dividing cells. HIV is one of the best examples of lenti-retrovirus.
RNA is the genetic composition of a lentivirus carries env, gag and pol genes.
However, HIV like lentivirus only infects the T cells.
Practically, using HIV for gene therapy is not a good choice.
The summery of the viral vectors:
|vector||DNA carrying capacity||Positives||Negatives|
|Adenovirus||8kb to 35kb||-Infect both dividings as well as non-dividing cells.
-Chance of infection is less
|-Provok strong immune response.
|AAV||Up to 4.5kb||-Longer transgene expression.
|-Smaller DNA carrying capacity.
-Required a helper virus
|Retrovirus||Less than 8kb||-Stable integration
-Infect replication cells
-Suitable for ex vivo treatment
-Can not infect non-dividing cells
-Provok immune response
|Lentivirus||8kb||-Infect proliferating, non-proliferating and bone marrow cells.
|-DNA carrying capacity is less.
-Chance of infection is high.
-Provok immune response.
-Higher DNA carrying capacity
-Suitable for in vivo gene therapy
|-Difficult to produce|
The image given below shows how the viral vectors insert the gene of interest into the host genome by interacting with the receptors present of the surface of the cell.
Liposome, naked DNA, nucleofection and transposons are some of the non-viral vector-mediated methods used for the gene therapy.
Why the non-viral vector will be one of the best opportunities for the gene transfer?
The non-viral vectors are non-toxic, non-immunogenic and tissue-specific. Also, it is easy to design and apply them. Some of the non-viral vectors are discussed here below,
The liposome also called lipoplex-mediated gene therapy is an artificial technique non-infected to the host cell.
The liposomes are artificially synthesized molecule typically 0.025 to 2 μm in size, made up of the lipids.
The DNA can not directly be inserted in the cell because the cell surface, as well as the DNA itself, has a negative charge.
Hence naturally both repel each other. The liposome is used to solve this problem.
The lipid molecule is hydrophilic as well as hydrophobic in nature which protects the interior aqueous phase.
The head of it is hydrophilic while the tail is hydrophobic.
The liquid solution of DNA is encapsulated with the liposome lipid bilayer which helps in penetrating it.
Nonetheless, due to the smaller size of it, the liposome is not a good choice for the larger size of gene transfer.
Also, the liposome is non-attractive for the DNA as well as the cell surface.
This problem is encountered by introducing a positive charge on the hydrophilic domain of the lipid.
A new type of upgraded version of the liposome is designed and named it as lipoplex.
The lipoplex attracts both the DNA as well as the cell surface, hence, a more stable complex of lipid-DNA is created.
This tube-like structure efficiently transfers DNA into the target cell. Plus, lipoplex is non-immunogenic.
Due to this reason, it is the best choice over the liposome and virus-based vector.
Furthermore, it is easy to prepare and can transfer a large amount of DNA.
The major disadvantage of the lipoplex is that it is not as efficient as the virus-based gene therapy.
Transposon-Mediated gene therapy is one of the emerging therapy after the CRISPR-CAS9.
The transposons are mobile genetic elements that can move from one location to another into the genome.
It also contains coding genes and terminal repeats as like the viruses. However, almost all transposons are inactive since long.
The scientist has discovered active transposons from the fish fossil and named it as sleeping beauty transposon.
The SB system is capable of inserting DNA into the host genome without any side effects.
It escapes the host immune system too and delivers a gene of interest efficiently at the target site.
Although the method still has many loopholes and limitations that need to be perfected before any pre-clinical trial.
The general mechanism of the SB system is shown into the figure below,
Nevertheless, The systems like SB transposon and CRISPR-CAS9 will become more effective in future.
We had explained sleeping beauty transposon in our previous article, the article contains all the information on the SB system, starting from their discovery to its mechanism of action.
During the experiments on mice, the scientist had observed that the naked DNA directly injected into the mice muscle cells through the lesions present on the cell surface.
Although theoretically, it should not possible as both the DNA and the cell surface contains negatively charged molecules that repel each other.
The scientist believes that naked DNA will be useful for the production of therapeutic proteins.
The transgene can be inserted into the muscle cell for the production of proteins such as insulin and thrombotic factors.
Nevertheless, enough research data are not available at present in favour of naked DNA use in gene therapy.
Read our article on naked DNA: Naked DNA Mediated Gene Therapy
Some of the other non-viral vectors mediated gene therapy methods are discussed here.
The non-viral vectors are further divided into three broader categories.
- Physical methods
- Chemical methods
- Synthetic molecules
1. Physical methods:
Several physical forces or procedures such as needle, gene gun, electroporation, ultra-sonication and laser photo-poration can be used in the gene transfer.
The first attempt of in vitro electroporation was done in the year 1982 whereas the first attempt for the in vivo electroporation was demonstrated in the year 1991. However, the method is known since 1960.
The basic method for both in vivo as well as in vitro electroporation is the same.
By applying the high electrical current for breaking the cell wall, pores are created on the surface of the cell.
The pores are formed within a second. The higher the pulse duration faster the pore forms.
The duration of pulse and amplitude decides permeability of the membrane for the gene transfer.
The transgene can be delivered either through intramuscularly of through intradermally. Sometimes intratumoral gene transfer can also be performed in case of cancer cells.
The electroporation readily delivered plasmid DNA into the cell. The field strength and the pulse vary from tissue type.
The in vivo electroporation method having a higher specificity and success rate directly injects the plasmid DNA into the target tissue.
Contrary, the method is restricted to some of the tissues, it is not accessible to the internal organs.
The in vitro electroporation is not as impressive as the in vivo therapy.
The method is also known as an electro-gene injection, electro-gene transfer or electrical mediated gene therapy.
The method is often known as sonication, was first described in the year 1954 for the transdermal drug delivery.
For the cellular DNA ingulf, a temporary cell membrane permeability is created using the ultrasonic waves.
After each round of sonication, the energy absorbed by the tissue results in the locally temporary heating that disrupts the cell membrane and produced pores. The process of sonoporation mediated cavitation is called acoustic-mediated cavitation.
The use of artificial microbubbles made up of lipid layer and gas-filled core makes the method more advanced and efficient.
The use of the surface stabilized such as synthetic lipid or polymers, phospholipid or albumin makes the microbubble more powerful for the gene therapy.
The transgene is introduced in the microbubbles by charge coupling, incorporating it into the shell or lumen.
The Microbubbles are 1 to 6 μm in diameter having white blood cell-like resemblance.
The success rate of the sonoporation depends on the:
- The intensity of the ultrasound
- Frequency of ultrasound
- Size of DNA to transfer
- The structure of the microbubble
- Duration of sonication
The method is highly site-specific, non-invasive and safer. Even the method is applicable for the internal organs also without any surgical operations.
The method is readily available for the vast majority of tissue types such as muscles, heart, cornea, brain and kidney tissues.
Furthermore, along with the microbubbles using tissue-specific receptors, antibody and ligands increase the specificity of the method.
The gene gun method is first introduced in the year 1987.
The method is also known as ballistic DNA transfer, micro-projectile gene transfer or DNA-coated particle bombardment.
Highly pressurized gas and metal ions are two components of the particle bombardment gene gun method. Also, instead of highly pressurized gas, electrical current or electrical discharge method can also be used.
The microparticles made up of silver, gold or tungsten deliver the transgene under the speed of highly pressurized gas (helium).
The Gene gun method is efficiently used for the intradermal, intramuscular or intratumor gene transfer.
The success rate of the present method depends on the gas pressure and velocity, size of the microparticle, sie of the transgene and the dose of injection.
1μm metal particles precisely transfer the transgene to the target. It is routinely used in ovarian cancer nowadays.
In the photoporation method, a transgene introduction is permitted by the laser-induced pores in the cell membrane.
The success of the gene delivery depends on the frequency of laser light and the focal length.
Due to the lack of the documented evidence and research data, the method is not used so often in gene therapy. Although, it is as effective as electroporation.
A large amount of DNA solution is directly injected via the hydrodynamic pressure. The pressure creates pore through which the DNA inserted into the host cell. The method is commonly for the gene transfer in the hepatic cells.
The needle method is first used for naked DNA insertion thus it is more suitable for gene insertion in skin, muscle, liver and cardiac cells.
The gene of interest injected directly through the needle without using any physical method. The method is simple yet effective.
However, the efficiency is too low as compared to other gene therapy vectors.
In this method, the magnetically charged particles copulated with the GOI. Under the higher magnetic field, the transgene inserted into the cell or cell line.
The magnetofection method is more suitable for ex vivo applications.
Some of the symbols used in this article:
2. Chemical method:
Here we are not discussing all the chemicals used in gene therapy. Gold particles, silver particles, silica and calcium phosphate are used as a chemical agent for gene delivering.
These particles efficiently transfer the gene into the cytosol by complexing with it or by protecting it from nucleases or other enzymes.
3. synthetic nanoparticles:
Synthetic nanoparticles are another optional source for gene delivering that are safer and easy to use.
Cyclodextrins like cyclic natural nanomaterial can interact with the DNA having low immunogenicity. Therefore it is one of the best naturally available nanomaterial for gene therapy.
It is very essential for a foreign particle to escape from the endocytosis, the process that kills it.
Polyethyleneimine (PEI) is a gene delivery vector helps in escaping GOI from the endosome. However, due to the presence of high positive charges on it, the vector is less effective.
Polyethyleneglycol (PEG) is one of the best nanoparticle used in gene therapy. It can efficiently transfer DNA to its target location.
It is majorly used in the delivery of siRNA.
Besides all these, Some of the peptides and proteins are also used for the gene transfer.
Other nano-particles such as dendrimers, polymethacrylate, chitosan and cationic synthetic lipids are used as gene delivery vehicle too.
The process of gene therapy:
Any of the gene therapy experiment can be divided into 5 different steps:
- Selection of GOI
- Selection of plasmid
- Selection of vector
- Selection of method
- Selection of technique
1. Selection of GOI:
One of the most crucial steps in the gene therapy experiment is selecting the gene of interest.
We have to select the appropriate GOI based on the disease type.
For instance, a single gene can be transferred efficiently rather than two or more gene. Therefore selecting monogenic disease yields more promising results.
Furthermore, the size of the gene also matters a lot to succeed in the experiment. The gene transfer efficiency of smaller fragments is very good as compared with larger DNA fragments.
The GOI must have the following characteristic
- The gene must have high AT-rich sequences.
- GC content must be less than 50%
- The gene must not contain a large number of exons
2. Selection of plasmid:
Plasmid plays an important role in delivering the gene of interest at its specific location into the host genome.
The plasmid selected for the experiment must have higher transgene carrying capacity.
Also, it possesses some of the important sequences needed to insert the DNA.
It must have,
- Promoter sequences (specific to the gene of interest)
- ITR (inverted terminal repeats) which is needed for the recognition of the target site in the genome.
- An antibiotic resistance gene
- Control elements
- Genes essential for viral enzymes.
3. Selection of vector:
Vector selection is another big factor for gene therapy. The vector selection process is based on the type of gene we want to insert.
Although the viral vector gives excellent delivery rate and integration efficiency. It is not so safe.
Furthermore, the selection of vector also based on the size of the GOI.
For instance, if the size of the transgene >35 kb, the adenovirus should not be recommended because the gene carrying capacity of it is lower than this.
4. Selection of method:
After selecting both GOI as well as the vector, decide the method of the gene transfer.
If the target tissue is a somatic cell, use the somatic cell gene transfer method.
Choosing ex vivo or in vivo is depends on the transgene which you want to insert.
For example, if the transgene is for cystic fibrosis, in vivo gene therapy method works excellently, however, the same method does fail for DMD or AIDS.
Contrary to this, the ex vivo gene therapy gives more precision for a disease like haemophilia.
The selection of the method is based on the:
- Type of disease
- Type of transgene
- Type of tissue
- Chance of infection
Generally, ex vivo gene therapy for AIDS does not recommend due to the high risk factor associated with it.
5. Selection of technique:
The fifth step of the gene therapy experiment is the selection of technique.
If the non-viral vector is selected as a method, you need one of the technique from sonication, electroporation, magnetoception, gene gun or liposome.
The DNA can not directly be inserted into the host cell, so we need to create pores on the cell surface.
The electroporation is the best technique for all type of gene transfer experiments with non-viral vectors.
Even, it works more efficiently along with the liposome too.
Experimental set up:
The experimental set up is as crucial as above listed steps.
For the gene therapy experiments we need a highly contaminant free, sterile and sophisticated setup.
A state of the art laboratory facilitating the gene therapy must be equipped with all the utilities and safety setups.
Also, the experiments must be performed under the supervision of the experts.
Steps of the gene therapy are shown in the figure below,
Possible applications of gene therapy:
The faulty or the mutated gene is replaced by the healthy gene using gene therapy method. The method can be used for the diagnosis of disease if approved globally.
It is used in the diagnosis of inherited diseases such as cystic fibrosis, Duchenne muscular dystrophy, muscular atrophy and haemophilia. Furthermore, efforts are being made to develop gene therapy against monogenic disorders such as thalassemia and sickle cell anaemia.
The in vivo gene therapy or viral vector-mediated gene therapy is a good option for treating diseases like Parkinson’s disease, Alzheimer’s disease and brain tumours.
Nowadays gene therapy opened doors for dentistry. It is used to grow new teeth, bone repair and teeth regeneration.
DNA vaccines are another futuristic application of gene therapy, a naked DNA is directly injected for the production of therapeutic proteins such as insulin and thrombotic factors.
Treating cancer using transgene is another utilisation of gene therapy in which the expression of an oncogene is suppressed by using a transgene.
Also, the infected cancerous cells are likewise killed by expressing a toxic producing gene into those cells. Consequently, it also promotes apoptosis of the infected cells.
In addition to this, cardiac disorders, neurological disorders, infectious disorders and autoimmune disorders can be treated using gene therapy methods.
Limitations of gene therapy:
Each type of gene therapy has different problems, therefore, fully functioning gene therapy is still not available for the clinical trial on humans.
The viral vectors used in gene therapy can infect the host cells and produce a strong immune response against it.
Furthermore, the transgene is not expressed all the time.
Due to the short-lived nature of transgene, the success rate of gene therapy is too low.
Gene transfer experiments are restricted to live human embryo because of the ethical issues associated with it.
Rapid integration of transgene is not possible, therefore, we don’t know when will the transgene be expressed.
Further, not all the cells of particular tissue accept the transgene.
Random integration to other location can produce an adverse effect, gene activation/deactivation or oncogene activation.
The cost of gene therapy is very high, at approximately $ 100,000 per therapy (the insurance company doesn’t cover it).
Challenges & future aspect of gene therapy:
Undoubtedly, gene therapy is an effective way to prevent any disorder but with it, so many challenges are involved.
Safety is one of the first challenge associated with it. The viral vector-based gene transfer is more effective but can infect the host cell or stimulate an immune response.
Therefore it is very important to design a safer vector.
Since non-targeted insertion can cause serious health problems, the GOI must be incorporated at a specific location.
It is also a challenging task to insert the gene at a specific location.
The gene must be inserted at a particular location, must switch on the normal function of it and does not interrupt in other gene’s function.
The new gene can perhaps raise the oncogene expression which results in carcinoma. Therefore, the insert should not be involved in the oncogenic activity.
Besides all these technical issues, the cost of gene therapy is a bigger challenge in commercialising it.
It costs more than $ 100,000 per gene therapy.
Predicting the future of gene therapy is quite difficult because the results are uncertain and scattered. Notwithstanding it will be a dream comes true for us if we succeed.
Many inherited disease can be treated alongside with life-threatening disorders like cancer.
Scientists are very close to treating monogenic disorders like cystic fibrosis and thalassemia. Furthermore, aggressive strategies for the DMD and other related disorder suggest that there will be a lot of progress observed in the coming years.
However, gene therapy can be also be practised incorrectly.
Gene therapy can be misused in enhancing athletic performance, increase longevity, stopping the ageing process and to gain more power (superhuman capability).
All these activities are un-natural and can unbalance the natural phenomenon, therefore, we have to use it from discretion.
Books on gene therapy you may like:
Inserting a transgene or replacing a faulty gene is a tedious phenomenon, which, requires, advance instrumentations, precisions, and expertise.
All actions are subjected to total aseptic conditions, a minor contamination/infection with a virus can contaminate the entire cell line and the patients too.
Altering the embryo and changing the genetic composition is unethical and against the natural laws. In broader prospects, the manifestation is through nature only, henceforth, the human rights wing and government both are on VETO for this.